Between bionerd51 and RNAi Analyst on their Twitter feeds. For those who have followed bionerd51 for some time, and are impressed with his grasp of the science/chemistry that Sarepta possesses, he's worthy of following on Twitter.
I would put more weight in the JPM-TMT's decision to go with Tekmira's ebola program over SRPT's than a curiously word PR.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of first-in-class
RNA-based therapeutics, announced today that its lead therapeutic drug
candidate for the Marburg virus, AVI-7288, demonstrated up to 100%
survival in a non-human primate (NHP) study exploring the drug's effect
when treatment is delayed to various time points post-infection. The
study demonstrated a significantly higher rate of survival among NHPs
treated with AVI-7288 compared to the placebo-treated group when
treatment was administered up to 96-hours post infection. Sarepta is
conducting this work under a U.S. Department of Defense (DoD) contract
managed by the Joint Project Manager Transformational Medical
Technologies (JPM-TMT) Project Management Office, a component of the
Joint Program Executive Office for Chemical and Biological Defense
"These results are unprecedented and demonstrate a compelling proof of
concept with our PMOplus(R) chemistry platform and its ability to treat
the most lethal and fast-acting viruses, without compromising efficacy of
survival even after up to a four-day delay in the initiation of
treatment," said Chris Garabedian, President and Chief Executive Officer
of Sarepta Therapeutics.
It sounds like the 96-hour post-exposure was 100% effective but one of the other time points was only 83%.
"This study showed a high degree of survival between 83% and 100% in each
of four post-exposure cohorts that received daily treatments with
AVI-7288 beginning one-, 24-, 48-, or 96-hours after infection, compared
to 0% survival in the placebo-treated control group."